| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100096 | Journal of Crohn's and Colitis | 2012 | 14 Pages |
Abstract
Adalimumab is effective and well-tolerated for inducing and maintaining clinical remission in Japanese patients with moderate to severe Crohn's disease. NCT00445939; NCT00445432.
Keywords
6-MercaptopurinemFASShort Form-36 Health Surveyevery other weekIBDQ5-ASACDAIAdalimumabSF-36HRQOLTPNAAABCGPPDMCsFAS6-MPAAA+Bacillus Calmette-GuérinInductionimmeowImmunomodulatorCrohn's diseasefull analysis setphysical component summarymental component summaryPCsMaintenancepurified protein derivativeInflammatory Bowel Disease QuestionnaireJapanTotal parenteral nutritionHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mamoru Watanabe, Toshifumi Hibi, Kathleen G. Lomax, Susan K. Paulson, Jingdong Chao, M. Shamsul Alam, Anne Camez, On behalf of the study investigators On behalf of the study investigators,